VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Summary

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).

Timeline

Start

2024-05-20

Primary completion

2027-06

Completion

2027-10

Drugs

Indications